In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL-2R) were determined by ELISA technique, and natural killer cell (NK) activity, by a 4-h chromium-51 release assay. Decrease of NK activity correlated with the augmentation of serum sIL-2R. After a 4-d stimulation with interleukin 2 CTCL patients' peripheral mononuclear cells (PMC) showed an increase of cytotoxic activity similar to that in healthy donors' PMC. Normal donors' PMC demonstrated a diminished IL-2-induced cytotoxic activity in 25% CTCL serum (sIL-2R of 3000, 7330, and 10700 U/mI, respectively) compared to control serum (sIL-2R of 400, 340, and 420 U/ml, respectively). IL-2-dependent proliferation of 2-d phytohemagglutinin (PHA) b...
We performed a phase Ia/Ib study of interleukin 2 (IL2) in patients with cancer. Single doses of IL2...
<p>Natural killer (NK) cell-based immunotherapy is a promising therapy for cancer patients. Inhibito...
PURPOSE In leukemic cutaneous T-cell lymphoma (L-CTCL), malignant T cells accumulate in the blood...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical course was documented by determin...
In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical course was documented by determin...
Summary Interleukin 2 (IL-2) immunotherapy has met with limited success in the treatment of renal ce...
A novel IL-2 receptor, distinct from the Tac protein, has been identified on the surface of purified...
IL-2 is a major growth factor for all T-cell subsets acting via a specific membrane receptor. To inv...
Soluble inhibitory factors (SIF) have been demonstrated in the sera of cancer patients, which interf...
The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum...
Serum levels of soluble interleukin-2 receptor (sIL-2R) have been evaluated in 33 patients with chro...
The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum...
We performed a phase Ia/Ib study of interleukin 2 (IL2) in patients with cancer. Single doses of IL2...
<p>Natural killer (NK) cell-based immunotherapy is a promising therapy for cancer patients. Inhibito...
PURPOSE In leukemic cutaneous T-cell lymphoma (L-CTCL), malignant T cells accumulate in the blood...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In patients with cutaneous T-cell lymphomas (CTCL), soluble interleukin-2 receptor serum levels (sIL...
In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical course was documented by determin...
In 24 patients with cutaneous T-cell lymphomas (CTCL) the clinical course was documented by determin...
Summary Interleukin 2 (IL-2) immunotherapy has met with limited success in the treatment of renal ce...
A novel IL-2 receptor, distinct from the Tac protein, has been identified on the surface of purified...
IL-2 is a major growth factor for all T-cell subsets acting via a specific membrane receptor. To inv...
Soluble inhibitory factors (SIF) have been demonstrated in the sera of cancer patients, which interf...
The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum...
Serum levels of soluble interleukin-2 receptor (sIL-2R) have been evaluated in 33 patients with chro...
The immunologic consequences of prolonged infusions of rIL-2 in doses that produce physiologic serum...
We performed a phase Ia/Ib study of interleukin 2 (IL2) in patients with cancer. Single doses of IL2...
<p>Natural killer (NK) cell-based immunotherapy is a promising therapy for cancer patients. Inhibito...
PURPOSE In leukemic cutaneous T-cell lymphoma (L-CTCL), malignant T cells accumulate in the blood...